Inhaled corticosteroids: potency, dose equivalence and therapeutic index
Open Access
- 28 May 2015
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 80 (3) , 372-380
Abstract
Glucocorticosteroids are a group of structurally related molecules that includes natural hormones and synthetic drugs with a wide range of anti‐inflammatory potencies. For synthetic corticosteroid analogues it is commonly assumed that the therapeutic index cannot be improved by increasing their glucocorticoid receptor binding affinity. The validity of this assumption, particularly for inhaled corticosteroids, has not been fully explored. Inhaled corticosteroids exert their anti‐inflammatory activity locally in the airways, and hence this can be dissociated from their potential to cause systemic adverse effects. The molecular structural features that increase glucocorticoid receptor binding affinity and selectivity drive topical anti‐inflammatory activity. However, in addition, these structural modifications also result in physicochemical and pharmacokinetic changes that can enhance targeting to the airways and reduce systemic exposure. As a consequence, potency and therapeutic index can be correlated. However, this consideration is not reflected in asthma treatment guidelines that classify inhaled corticosteroid formulations as low‐, mid‐ and high dose, and imbed a simple dose equivalence approach where potency is not considered to affect the therapeutic index. This article describes the relationship between potency and therapeutic index, and concludes that higher potency can potentially improve the therapeutic index. Therefore, both efficacy and safety should be considered when classifying inhaled corticosteroid regimens in terms of dose equivalence. The historical approach to dose equivalence in asthma treatment guidelines is not appropriate for the wider range of molecules, potencies and device/formulations now available. A more robust method is needed that incorporates pharmacological principles.Keywords
Funding Information
- GlaxoSmithKline
This publication has 42 references indexed in Scilit:
- The Relationship Between Fluticasone Furoate Systemic Exposure and Cortisol SuppressionClinical Pharmacokinetics, 2013
- Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthmaRespiratory Research, 2011
- Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoateRespiratory Research, 2007
- Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroidsJournal of Pharmaceutical and Biomedical Analysis, 2006
- Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionateClinical Therapeutics, 2006
- Single‐Dose and Steady‐State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as Diskus® or Turbohaler® Dry‐Powder Inhalers to Healthy SubjectsThe Journal of Clinical Pharmacology, 2001
- Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patientsAnnals of Allergy, Asthma & Immunology, 2001
- Triamcinolone AcetonideDrugs, 1997
- Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled AdministrationThe Journal of Clinical Pharmacology, 1995
- Nasal Mucosal Inflammation Has No Effect on the Absorption of Intranasal Triamcinolone AcetonideThe Journal of Clinical Pharmacology, 1994